Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down
Health & Biotech
Health & Biotech
It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining.
Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by Rhinomed (ASX:RNO) up 23.53% and Stemcell United (ASX:SCU) up 18.75% – but all on no news.
The next cab off the ranks was Rhythm Biosciences (ASX:RHY) which rose 16.28% on the news it has established a US entity – IchorDX, Inc – as part of its plans to expand into the American market.
The company says the US represents one of the largest diagnostic markets in the world, with a current addressable market of over 94 million people.
“The establishment of IchorDX, Inc., in the US demonstrates our commitment to accelerate our international expansion plans, offer additional optionality to our corporate structure and aim to create a global footprint for Rhythm’s transformative cancer detection technology,” Rhythm CEO Glenn Gilbert said.
“The reality is that the global need for a simple and accurate mass screening blood test for colorectal cancer is growing. This first step to enter the US market moves Rhythm closer to meeting this need.”
Plus, the market could grow in the short term by a further 21%, following the US Preventative Services Task Force recommendation that the colorectal cancer screening age be reduced from 50 to 45 years of age.
LBT Innovations (ASX:LBT) was up 11.11% after it presented data from five clinical studies featuring the Automated Plate Assessment System (APAS) at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from 9-12 July.
“Application of the APAS® technology to early culture reads has the potential to further disrupt the current application of testing in clinical laboratories, with the potential to improve patient care through faster turnaround of results,” LBT scientific director Dr Steven Giglio said.
Up 10.87% was Recce Pharma (ASX:RCE) which recently announced multiple patients have been dosed with RECCE 327 (R327) in a topical Phase I/II clinical trial at the Fiona Stanley Hospital Burns Unit in Perth, Western Australia.
The company also announced R327 had demonstrated “outstanding efficacy against necrotizing fasciitis ‘flesh eating’ bacteria” – as well as an anti-viral patent being granted in China for its synthetic anti-infectives.
Lifespot Health (ASX:LSH) rose 10.53% after news it had appointed two new board members in Dr Andrew Saich and Darryl Davies.
Proteomics (ASX:PIQ) jumped 9.73% off the back of news its diabetes treatment lowers the PromarkerD scores of patients with type 2 diabetes taking canagliflozin, an SGLT2-inhibitor diabetes drug.
And Hexima (ASX:HXL) was up 9.09% with plans to present further analysis of the clinical data from its Phase I/IIa clinical trial of pezadeftide (HXP124) for the treatment of onychomycosis at the upcoming American Podiatric Medical Association (APMA) meeting in Aurora, Colorado.
Then there was MGC Pharma (ASX:MXC), up 7.89% after submitting a patent application for its cannabinoid drug delivery system to the European IP office.
Here’s a table showing how ASX-listed healthcare stocks have been performing.
Code | Company | Price | %Wk | %Yr | MktCap |
---|---|---|---|---|---|
ALT | Analytica Limited | 0.0025 | 25.00% | 25.00% | $11,534,503 |
RNO | Rhinomed Ltd | 0.21 | 23.53% | 159.26% | $53,299,918 |
SCU | Stemcell United Ltd | 0.019 | 18.75% | 26.67% | $18,779,772 |
RHY | Rhythm Biosciences | 1 | 16.28% | 988.44% | $206,214,227 |
EPN | Epsilon Healthcare | 0.15 | 15.38% | -45.45% | $27,942,508 |
S66 | Star Combo | 0.29 | 13.73% | -23.68% | $39,066,616 |
AT1 | Atomo Diagnostics | 0.185 | 12.12% | -54.88% | $77,651,164 |
AVE | Avecho Biotech Ltd | 0.02 | 11.11% | 185.71% | $36,722,331 |
LBT | LBT Innovations | 0.11 | 11.11% | -26.67% | $33,248,244 |
RCE | Recce Pharmaceutical | 1.02 | 10.87% | -26.62% | $166,826,733 |
LSH | Lifespot Health Ltd | 0.105 | 10.53% | 170.42% | $16,846,696 |
PIQ | Proteomics Int Lab | 1.015 | 9.73% | 120.65% | $108,362,051 |
HXL | Hexima | 0.18 | 9.09% | -40.98% | $22,268,896 |
MXC | Mgc Pharmaceuticals | 0.041 | 7.89% | 70.83% | $92,990,042 |
MEM | Memphasys Ltd | 0.07 | 7.69% | -27.08% | $53,184,172 |
4DX | 4Dmedical Limited | 1.49 | 7.58% | 0.00% | $310,829,262 |
ZNO | Zoono Group Ltd | 0.725 | 7.41% | -69.54% | $117,966,211 |
OSP | Osprey Med Inc | 0.015 | 7.14% | -68.09% | $38,486,704 |
GLH | Global Health Ltd | 0.525 | 6.06% | 84.21% | $26,002,245 |
MVF | Monash IVF Group Ltd | 0.8575 | 5.86% | 61.79% | $327,293,266 |
IHL | Incannex Healthcare | 0.275 | 5.77% | 292.86% | $291,591,509 |
NTI | Neurotech Intl | 0.056 | 5.66% | 460.00% | $39,021,871 |
1ST | 1St Group Ltd | 0.021 | 5.00% | -44.74% | $8,916,955 |
MMJ | MMJ Group Hlds Ltd | 0.085 | 4.94% | -19.05% | $19,086,181 |
RAP | Resapp Health Ltd | 0.045 | 4.65% | -67.86% | $37,804,671 |
PGC | Paragon Care Limited | 0.285 | 3.64% | 62.86% | $97,986,735 |
VBS | Vectus Biosystems | 1.345 | 3.46% | 97.79% | $42,576,505 |
SHG | Singular Health | 0.3 | 3.45% | 0.00% | $18,605,545 |
CDY | Cellmid Limited | 0.061 | 3.39% | -53.18% | $11,058,403 |
IDT | IDT Australia Ltd | 0.325 | 3.17% | 116.67% | $76,755,254 |
CPH | Creso Pharma Ltd | 0.1375 | 1.85% | 358.33% | $160,778,469 |
HCT | Holista CollTech Ltd | 0.059 | 1.72% | -28.92% | $15,970,247 |
BPH | BPH Energy Ltd | 0.074 | 1.37% | 401.90% | $47,874,196 |
CYC | Cyclopharm Limited | 1.68 | 1.20% | 14.29% | $156,869,703 |
BWX | BWX Limited | 5.14 | 1.18% | 18.43% | $719,253,770 |
RAC | Race Oncology Ltd | 3.55 | 1.14% | 260.41% | $506,846,959 |
NEU | Neuren Pharmaceut. | 1.595 | 0.95% | 31.82% | $182,226,892 |
ARX | Aroa Biosurgery | 1.21 | 0.83% | 0.00% | $365,807,475 |
AC8 | Auscann Grp Hlgs Ltd | 0.11 | 0.00% | -26.67% | $46,257,447 |
ADR | Adherium Ltd | 0.018 | 0.00% | -30.77% | $38,263,196 |
AHK | Ark Mines Limited | 0.034 | 0.00% | 0.00% | $1,778,920 |
ANP | Antisense Therapeut. | 0.2 | 0.00% | 81.82% | $112,022,887 |
ATX | Amplia Therapeutics | 0.21 | 0.00% | 31.25% | $26,212,481 |
BNO | Bionomics Limited | 0.185 | 0.00% | 217.03% | $191,443,381 |
CAJ | Capitol Health | 0.37 | 0.00% | 76.19% | $375,255,592 |
CDX | Cardiex Limited | 0.068 | 0.00% | 112.50% | $63,896,633 |
DVL | Dorsavi Ltd | 0.028 | 0.00% | 4.59% | $9,826,112 |
FFC | Farmaforce Ltd | 0.067 | 0.00% | 21.82% | $8,755,626 |
GSS | Genetic Signatures | 1.34 | 0.00% | -44.40% | $192,924,782 |
GTG | Genetic Technologies | 0.008 | 0.00% | -30.43% | $72,133,814 |
ICS | ICSGlobal Limited | 0.575313 | 0.00% | 28.82% | $6,054,605 |
IMC | Immuron Limited | 0.16 | 0.00% | -27.27% | $36,359,455 |
IVX | Invion Ltd | 0.014 | 0.00% | 55.56% | $77,553,592 |
LCT | Living Cell Tech. | 0.014 | 0.00% | -12.50% | $8,000,174 |
MDR | Medadvisor Limited | 0.3 | 0.00% | -37.89% | $113,214,905 |
OIL | Optiscan Imaging | 0.225 | 0.00% | 378.72% | $141,831,938 |
PAL | Palla Pharma Ltd | 0.38 | 0.00% | -54.33% | $59,907,870 |
PBP | Probiotec Limited | 2.1 | 0.00% | 3.96% | $162,419,250 |
VHT | Volpara Health Tech | 1.14 | 0.00% | -17.99% | $291,525,494 |
PAA | Pharmaust Limited | 0.093 | -1.06% | -54.63% | $30,406,072 |
SDI | SDI Limited | 0.88 | -1.12% | 26.62% | $104,601,666 |
VTI | Vision Tech, Inc | 1.12 | -1.32% | -37.78% | $27,771,713 |
ONE | Oneview Healthcare | 0.37 | -1.33% | 987.08% | $155,975,491 |
AGH | Althea Group | 0.335 | -1.47% | -6.94% | $86,583,268 |
RSH | Respiri Limited | 0.067 | -1.47% | -53.79% | $47,707,492 |
NOX | Noxopharm Limited | 0.6 | -1.64% | 81.82% | $177,256,362 |
OSL | Oncosil Medical | 0.059 | -1.67% | -48.70% | $48,637,941 |
ONT | 1300 Smiles Limited | 6.88 | -1.71% | 33.85% | $162,196,930 |
ACR | Acrux Limited | 0.1325 | -1.85% | -17.19% | $36,829,701 |
NXS | Next Science Limited | 1.55 | -1.90% | 21.09% | $314,778,515 |
CGS | Cogstate Ltd | 1.4 | -2.10% | 250.00% | $233,399,072 |
BD1 | Bard1 Life Sciences | 1.805 | -2.17% | 100.56% | $145,703,221 |
PAR | Paradigm Bio. | 1.97 | -2.48% | -31.12% | $444,232,947 |
APH | AP Hemp Ltd | 0.38 | -2.56% | 181.48% | $29,799,953 |
IBX | Imagion Biosys Ltd | 0.0875 | -2.78% | 82.29% | $90,711,849 |
CBL | Control Bionics | 0.64 | -3.03% | 0.00% | $31,637,905 |
MDC | Medlab Clinical Ltd | 0.16 | -3.03% | 14.29% | $54,748,107 |
PCK | Painchek Ltd | 0.059 | -3.28% | -48.70% | $65,354,678 |
AHC | Austco Healthcare | 0.145 | -3.33% | 113.24% | $44,049,287 |
BIT | Biotron Limited | 0.058 | -3.33% | -42.00% | $41,414,030 |
BXN | Bioxyne Ltd | 0.029 | -3.33% | 163.64% | $18,564,217 |
DOC | Doctor Care Anywhere | 0.855 | -3.93% | 0.00% | $148,739,257 |
CYP | Cynata Therapeutics | 0.485 | -3.96% | -30.51% | $71,638,297 |
JHC | Japara Healthcare Lt | 1.21 | -3.97% | 146.94% | $331,386,687 |
EXL | Elixinol Wellness | 0.12 | -4.00% | -25.00% | $37,807,578 |
ZLD | Zelira Therapeutics | 0.048 | -4.00% | -9.43% | $57,135,502 |
VLS | Vita Life Sciences.. | 1.07 | -4.04% | 94.55% | $55,811,769 |
ACW | Actinogen Medical | 0.11 | -4.35% | 388.02% | $182,661,440 |
NSB | Neuroscientific | 0.32 | -4.48% | 48.84% | $47,345,642 |
NC6 | Nanollose Limited | 0.085 | -4.49% | 102.38% | $12,935,714 |
ILA | Island Pharma | 0.315 | -4.55% | 0.00% | $14,171,245 |
IMU | Imugene Limited | 0.315 | -4.55% | 728.95% | $1,621,937,450 |
OVN | Oventus Medical Ltd | 0.105 | -4.55% | -59.62% | $26,589,919 |
KZA | Kazia Therapeutics | 1.23 | -4.65% | 156.70% | $168,341,305 |
IMM | Immutep Ltd | 0.5 | -4.76% | 177.78% | $377,817,232 |
IPD | Impedimed Limited | 0.1 | -4.76% | 47.06% | $156,869,632 |
RGS | Regeneus Ltd | 0.075 | -5.06% | -12.79% | $22,765,377 |
RHT | Resonance Health | 0.165 | -5.71% | 10.00% | $78,344,837 |
TRU | Truscreen | 0.064 | -5.88% | 0.00% | $23,223,440 |
OPT | Opthea Limited | 1.245 | -6.04% | -44.67% | $438,754,426 |
MX1 | Micro-X Limited | 0.31 | -6.06% | 110.17% | $147,104,557 |
CMP | Compumedics Limited | 0.385 | -6.10% | -8.33% | $68,207,735 |
ADO | Anteotech Ltd | 0.225 | -6.25% | 603.13% | $449,240,590 |
TLX | Telix Pharmaceutical | 5.25 | -6.42% | 286.03% | $1,427,830,679 |
CHM | Chimeric Therapeutic | 0.29 | -6.45% | 0.00% | $60,034,161 |
PYC | PYC Therapeutics | 0.145 | -6.45% | 27.03% | $477,138,915 |
ALC | Alcidion Group Ltd | 0.36 | -6.49% | 132.26% | $377,304,859 |
CTE | Cryosite Limited | 0.4 | -6.98% | 185.71% | $18,743,825 |
PSQ | Pacific Smiles Grp | 2.4 | -6.98% | 53.85% | $394,167,387 |
OCC | Orthocell Limited | 0.515 | -7.21% | 49.28% | $100,056,679 |
UBI | Universal Biosensors | 0.75 | -7.41% | 240.91% | $135,924,065 |
EYE | Nova EYE Medical Ltd | 0.3 | -7.69% | -14.63% | $43,105,841 |
ICR | Intelicare Holdings | 0.175 | -7.89% | -58.82% | $8,451,114 |
DXB | Dimerix Ltd | 0.23 | -8.00% | -31.34% | $47,519,831 |
CAN | Cann Group Ltd | 0.365 | -8.75% | -49.31% | $102,827,439 |
PXS | Pharmaxis Ltd | 0.081 | -8.99% | -5.81% | $37,139,781 |
AMT | Allegra Orthopaedics | 0.2 | -9.09% | -16.67% | $20,891,841 |
SOM | SomnoMed Limited | 2.25 | -9.27% | 73.75% | $192,001,611 |
MVP | Medical Developments | 4.03 | -9.44% | -35.21% | $297,886,329 |
PNV | Polynovo Limited | 2.155 | -9.45% | -4.65% | $1,408,756,534 |
BOT | Botanix Pharma Ltd | 0.076 | -10.59% | 49.02% | $73,958,798 |
PTX | Prescient Ltd | 0.21 | -10.64% | 262.07% | $134,704,302 |
TD1 | Tali Digital Limited | 0.033 | -10.81% | 26.92% | $30,752,891 |
EZZ | EZZ Life Science | 0.41 | -10.87% | 0.00% | $5,220,000 |
MEB | Medibio Limited | 0.008 | -11.11% | -33.33% | $14,360,492 |
NYR | Nyrada Inc. | 0.295 | -11.94% | 55.26% | $35,027,311 |
JTL | Jayex Technology Ltd | 0.029 | -12.12% | 0.00% | $6,393,160 |
OSX | Osteopore Limited | 0.42 | -12.50% | -31.15% | $33,556,254 |
M7T | Mach7 Tech Limited | 0.9 | -12.62% | 9.09% | $227,037,807 |
ATH | Alterity Therap Ltd | 0.033 | -13.16% | -10.81% | $81,833,736 |
PAB | Patrys Limited | 0.047 | -14.55% | 264.01% | $89,160,248 |
SUD | Suda Pharmaceuticals | 0.053 | -17.19% | 76.67% | $27,406,739 |
1AD | Adalta Limited | 0.115 | -17.86% | 16.10% | $33,099,243 |
Flat this fortnight was Auscann (ASX:AC8) even after news it had submitted its first module to the Australian Pesticides and Veterinary Medicines Association (APVMA) to commence the submission of its dossier for the registration of DermaCann – in development for anti-inflammatory and immune support in dogs with dermatological conditions.
Apparently, no one cares much that there are approximately 1 million dogs in Australia who suffer from dermatological conditions…
Maybe investors will perk up a bit when they realise the global canine skin and dermatitis market is worth an estimated US$1.5 billion globally.
Trailing the flatline pack was Adherium (ASX:ADR) with news the off-market takeover bid from Respiri (ASX:RSH) had lapsed.
Adalta (ASX:1AD) was the biggest loser, down 17.86% following the news it plans to progress the inhaled version of its AD-214 treatment into efficacy studies for Idiopathic Pulmonary Fibrosis (IPF).
It was followed closely by Suda Pharma (ASX:SUD), down 17.19% on no news.
Patrys (ASX:PAB) dropped 14.55% despite new data from non-clinical studies confirming its full-sized IgG deoxymab antibody, PAT-DX3, is able to cross the blood-brain barrier (BBB) in an animal model of primary brain cancer (glioblastoma multiforme, GBM).
And Alterity Therapeutics (ASX:ATH) followed, down 13.16% even after publishing data demonstrating its ATH434 treatment for Multiple System Atrophy (MSA) is neuroprotective and improves motor function.